All Stories

Mineralys’ stock jumps as hypertension drug posts double clinical wins

Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase inhibitor chalked up wins in two types of hypertension.

Mar 10, 2025 - 15:02
 0
Mineralys’ stock jumps as hypertension drug posts double clinical wins
Mineralys Therapeutics enjoyed a big stock bump after its aldosterone synthase inhibitor chalked up wins in two types of hypertension.
Read More

Tags:

Previous Article

Neurotech nabs FDA approval to treat rare eye disorder with cell therapy implant...

Next Article

STAT+: Mineralys Therapeutics stock soars on blood pressure drug data

Related Posts

Gilead loses interest in Arcus' kidney cancer rival to Merck's Welireg

Gilead loses interest in Arcus' kidney cancer rival to ...

Feb 18, 2025  0

Insilico Medicine provides benchmark timelines from its 22 AI-designed drug candidates

Insilico Medicine provides benchmark timelines from its...

Feb 11, 2025  0

AstraZeneca, eyeing $5B peak sales, reports phase 3 breast cancer win for oral SERD

AstraZeneca, eyeing $5B peak sales, reports phase 3 bre...

Feb 26, 2025  0